Literature DB >> 1868046

Unusual gastrointestinal complications of interleukin-2 therapy.

R Rahman1, Z Bernstein, L Vaickus, R Penetrante, S Arbuck, I Kopec, D Vesper, H O Douglass, K A Foon.   

Abstract

Minor and reversible gastrointestinal side effects are common when patients receive interleukin-2 (IL-2) with or without lymphokine-activated killer (LAK) cells. We treated 42 cancer patients with IL-2 therapy and 3 patients developed serious gastrointestinal problems during treatment. Complications included sigmoid colon perforation, ischemic necrosis of the small and large intestine, and diffuse bowel ulceration. These were not associated with tumor implants or hypotension. Two patients died as a direct result of these problems despite aggressive surgical and medical management. The incidence of major gastrointestinal complications with IL-2 therapy may be greater than previously reported and a heightened awareness of potential gastrointestinal problems may circumvent considerable morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868046     DOI: 10.1097/00002371-199106000-00009

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  4 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 2.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

3.  Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases.

Authors:  Yue Hu; Noah Feit; Yanqin Huang; Wenhong Xu; Shu Zheng; Xiuzhen Li
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

4.  High-dose interleukin 2 promotes bacterial translocation from the gut.

Authors:  J V Reynolds; P Murchan; N Leonard; D B Gough; P Clarke; F B Keane; W A Tanner
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.